Morphosys gets a major tafasitamab endorsement
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Clinical developments over the Christmas period
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Corporate and regulatory developments over the Christmas period
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Why a 2020 spotlight will fall on tafasitamab
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Biogen stacks the deck but the path forward is no clearer in Alzheimer’s
The presentation of Biogen’s hugely complex aducanumab pivotal programme confirms that the US regulator is destined to make another polarising decision.
Go or no go? Vascepa’s finale and Allergan's pain relief
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Roxadustat moves on to the regulators
A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…
Vascepa's future could hinge on next week's panel
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
Go or no go? Agile and Lipocine hope to make it third time lucky
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.